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OBJECTIVE: To investigate the outcomes of childhood diffuse endocapillary proliferation Henoch-Scho¨nlein
purpura nephritis (DEP-HSPN) in response to early diagnosis and prompt treatment.
METHODS: Eleven cases of DEP-HSPN in children were investigated in comparison to HSPN without diffuse
endocapillary proliferation (non-DEP-HSPN).
RESULTS: DEP-HSPN had a higher prevalence of nephrotic syndrome but a lower prevalence of hematuria
compared to non-DEP-HSPN. IgA, IgG and IgM antibody deposition was found in DEP-HSPN by histopatho-
logical examination. Proteinuria cleared in all 11 cases through treatment with steroids and/or immuno-
suppressive drugs. However, half of the DEP-HSPN patients continuously had hematuria after treatment.
CONCLUSION: The early diagnosis and prompt initiation of immunosuppressive treatment based on renal
biopsy are important for achieving favorable outcomes.
KEYWORDS: Henoch-Scho¨nlein Purpura Nephritis; Diffuse Endocapillary Proliferation; Renal Biopsy.
Fu H, Mao J, Xu Y, Gu W, Zhu X, Liu A. Clinical features and outcomes of diffuse endocapillary proliferation Henoch-Scho¨nlein purpura nephritis
in children. Clinics. 2016;71(9):550-554
Received for publication on March 11, 2016; First review completed on April 16, 2016; Accepted for publication on April 29, 2016
*Corresponding author. E-mail: maojianhua151103@163.com
’ INTRODUCTION
Henoch-Schönlein purpura (HSP) is an immunoglobulin A
(IgA)-mediated, systemic small-vessel vasculitis that occurs
in children (1). The deposition of IgA antibodies in vessel
walls leads to symptoms involving the skin, joints, intestines
and kidneys (2). Henoch-Schönlein purpura nephritis (HSPN),
which is defined as HSP for 6 months with kidney involve-
ment, including hematuria and/or proteinuria, is the most
serious complication and often determines the prognosis of
an HSP patient (1,2).
The progression of renal involvement is important in
evaluating HSPN prognosis and in selecting individualized
therapeutic strategies. The clinical manifestations of HSPN
are miscellaneous and the pathological features are divergent
(3,4). In addition, the severity of the clinical manifestations of
HSPN in children does not always correlate with the severity
of the pathological renal biopsy findings (3). HSPN with
diffuse endocapillary proliferation (DEP-HSPN) may have a
different prognosis than HSPN without diffuse endocapillary
proliferation (non-DEP-HSPN). Therefore, in the current study,
the pathological features and corresponding clinical mani-




From December 2007 to November 2013, 4212 HSP
patients were hospitalized in the Children’s Hospital, School
of Medicine, Zhejiang University. Of these patients, 1823
were diagnosed with HSPN and 503 cases were further
confirmed by renal biopsy with indications of the following
diseases or manifestations: 1) nephritic syndrome; 2) moderate
or severe proteinuria; 3) acute nephritis; or 4) rapidly
progressive glomerulonephritis. The 503 patients were
enrolled into the current study and grouped as DEP-HSPN
(n=11) and non-DEP-HSPN (n=492). Awritten consent form
was obtained from each patient’s parents. The study
protocol was approved by the Ethics Committee of Zhejiang
University. The diagnosis of HSP fulfills the criteria for
the classification of childhood vasculitis (5). The inclusion
criteria for this prospective study were as follows:
1) patients were p16 years old; 2) patients presented with
typical palpable purpura or petechiae and at least one of the
following: arthralgia or arthritis, abdominal pain or renal
involvement. The following diseases were excluded: thrombo-
cytopenia, post-streptococcus-infection glomerulonephritis,
Parvovirus B19 infection, lupus nephritis, ANCA-associated
nephritis, hepatitis B-induced nephritis, and coagulopathy.DOI: 10.6061/clinics/2016(09)11
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HSPN was defined as the presence of gross or microscopic
hematuria (45 erythrocytes per high-power field) with or
without proteinuria (44 mg/kg/d), nephrotic syndrome
(urine protein 450 mg/kg/d, serum albumin o2.5 g/dL,
edema and hyperlipidemia), or acute nephritis (hematuria
plus at least one of the following: increased serum creatinine,
hypertension, or oliguria).
Histopathology
Kidney biopsies were obtained from all 503 patients and
were stained with hematoxylin and eosin (H&E) and for
immunofluorescence (IF). IF staining was performed on
3-mm cryostat sections using polyclonal fluorescein-isothio-
cyanate-conjugated antibodies to IgG, IgA, IgM, C3, C4, C1q
and fibrinogen according to the manufacturer’s instruc-
tions (DakoCytomation, Glostrup, Denmark). The intensity
of IF staining was subjectively scored on scale of 0-3. The
International Study of Kidney Disease in Children classifica-
tion was used to classify HSPN (6).
Statistical analysis
Chi-squared tests or student’s two-tailed t tests were
performed. P values less than 0.05 were considered signifi-
cant. All data analysis was carried out using the SPSS soft-
ware for windows (version 13.0; SPSS, Inc., Chicago, IL).
’ RESULTS
A total of 11 (4 girls and 7 boys) out of the 503 HSPN
patients were given a confirmative diagnosis of DEP-HSPN,
and the remaining 492 patients were diagnosed with non-
DEP-HSPN. All DEP-HSPN patients had typical manifesta-
tions of HSP during the clinical visit, including skin rash,
abdominal pain and joint symptoms. As shown in Table 1,
of the 11 patients, 36.36% (4/11) had edema, 45.45% (5/11)
had hypertension, 27.27% had gross hematuria, 72.73%
had severe proteinuria (^50 mg/kg/d), 18.18% (2/11) had
moderate proteinuria (^25 mg/kg/d, but o50 mg/kg/d),
9.09% (1/11) had mild proteinuria (o25 mg/kg/d), 27.27%
(3/11) had albumin deficiency, and 9.09% (1/11) had acute
renal dysfunction. The diagnosis of DEP-HSPN was patho-
logically confirmed by kidney biopsy in all 11 patients, and
diffuse endocapillary proliferation was easily observed in
the cases of DEP-HSPN via H&E staining (Figure 1A) and
periodic acid-Schiff (PAS) staining (Figure 1B). In contrast,
non-DEP-HSPN was characterized by the significant pro-
liferation of mesangial cells, as indicated by H&E staining
(Figure 1C) and PAS staining (Figure 1D).
As shown in Table 2, crescent formation was found in
2 of the 11 specimens and affected an average of 1.06%
glomeruli (range: 0-7.69%). The clinical impact of crescent
formation was not analyzed due to the limited number of
cases. Of the 11 cases of DEP-HSPN, 9 were class IIb and 2
were class IIIb.
The IF staining indicated that 3 patients (27.27%) were
positive for IgA, 4 cases (36.36%) were positive for IgA and
IgG, 2 cases (18.18%) were positive for IgA and IgM, and
2 cases (18.18%) were positive for IgA, IgM, and IgG (Table 2).
In addition, C3 deposits were found in 10 out the 11 patients
(90.90%) (Table 2).
Compared to non-DEP-HSPN at the IIb stage (43 cases),
DEP-HSPN (9 cases) had a higher prevalence of nephrotic
syndrome (32.6% of non-DEP-HSPN vs 77.8% of DEP-HSPN,
p=0.012) but a lower prevalence of hematuria (60.5% of non-
DEP-HSPN vs 11.1% of DEP-HSPN, p=0.007, Table 3).
Of the 11 DEP-HSPN patients, 3 patients received
methylprednisolone pulse therapy followed by prednisone
and cyclophosphamide (CTX), 2 patients received predni-
sone plus mycophenolate mofetil (MMF), 3 patients were
treated with prednisone plus Tripterygium, 2 patients were
treated only with Tripterygium, and one patient was treated
only with prednisone. In addition, all 11 patients were given
angiotensin-converting enzyme inhibitors. As shown in
Table 4, 6 patients still had hematuria after 13-20 months of
treatment with MMF alone (3 cases), prednisone alone
(1 case), Tripterygium alone (1 case), or methylprednisolone,
prednisone, and CTX (1 case). The remaining 5 patients’
urine test results were normal after 7-17 months of treatment
with Tripterygium alone (3 cases) or methylprednisolone,
prednisone, and CTX (2 cases).
’ DISCUSSION
The histopathological feature of HSP is the deposition of
immune complexes on organs such as the skin and glomeruli
(7). Glomerular nephritis in HSP patients, known as HSPN,
occurs in approximately 33% of pediatric cases and approxi-
mately 63% of adult cases (8). The current study reviewed
11 cases of DEP-HSPN and 492 cases of non-DEP-HSPN.
Compared to non-DEP-HSPN, DEP-HSPN had a higher
prevalence of nephrotic syndrome and IgA, IgG and IgM
antibody deposition but a lower prevalence of hematuria.
After pulse steroid therapy followed by standard therapy
with steroids with or without immunosuppressive drugs,
proteinuria disappeared in all 11 cases. However, half of the
Table 1 - Clinical presentation of DEP-HSPN patients.
ID # Age (yr) Sex RBT (w) Symptoms HP ED GH PU AD RD
1 5.9 M 4 Severe
2 13.4 M 3 Arthralgia Mild
3 5.4 M 6 + + Severe
4 5.4 M 3 Severe
5 10.8 F 3 Abdominal pain + Moderate
6 10.6 M 9 + Severe +
7 7.9 F 3 + Severe +
8 12.0 F 6 + + Severe +
9 7.7 F 12 Abdominal pain, arthralgia, + Moderate
10 9.1 M 3 Abdominal pain, arthralgia, + + + Severe +
11 9.2 M 2 Arthralgia + Severe
RBT: time gap between clinical diagnosis to renal biopsy confirmation (weeks); HP: hypertension; ED: edema; GH: gross hematuria; PU: proteinuria; AD:
albumin deficiency; RD: renal dysfunction.
551
CLINICS 2016;71(9):550-554 Diffuse endocapillary proliferation HSPN in children
Fu et al.
DEP-HSPN patients continuously had hematuria, suggest-
ing that hematuria in DEP-HSPN requires a more effective
treatment and a longer follow-up period.
Steroid therapy is recommended for HSP patients with
severe renal damage (9,10). Patients refractory to steroids
may be successfully treated with immunosuppressive agents
(11,12). However, there are few reports on the findings of
histopathological improvement that demonstrate the effec-
tiveness of immunosuppressive therapy for HSPN. In this
regard, while 93.9% of pediatric HSPN patients and 89.2% of
adult HSPN patients achieve short-term remission (13), the
long-term prognosis is not always encouraging, especially in
cases of adult onset. A survival rate of 74% and a complete
remission rate of only 20% over a median observation period
of 15 years were reported by Sherestha et al. (14). Consi-
stently, we found that only half of the 11 DEP-HSPN cases
became negative for hematuria in response to the steroid
treatment with or without immunosuppressive drugs,
suggesting that a longer follow-up period is required in
DEP-HSPN patients.
The degrees of crescent formation, interstitial fibrosis and
diffuse endothelial cell proliferation are important in
predicting HSPN prognosis (14). In this context, chronic
proteinuria greater than 1 g/day and/or accompanying
nephrotic syndrome predict a poor HSPN prognosis (15).
Therefore, it has been recommended that the treatment plan
should be determined based on the clearance of or at least a
reduction in proteinuria to less than 1 g/day. In the present
study, proteinuria was completely cleared in DEP-HSPN
patients after treatment with a single reagent or a com-
bination of steroids and immunosuppressive drugs, sug-
gesting that the strategies used in the current study,
Table 2 - Histopathological examination in DEP-HSPN patients.
ID# Immunostaining Stage Crescent Time for clearance of proteinuria (Months)
1 IgA+++, IgM+, C3++ IIIb 1/25 4
2 IgA+++, C3++ IIb 0/11 2
3 IgG+, IgA+++, IgM+-, C3+++ IIb 0/9 4
4 IgG+, IgA++, C3++ IIIb 1/13 5
5 IgA++, C3++ IIb 0/30 1
6 IgA+++, IgM+, C3++ IIb 0/17 5
7 IgG+, IgA+++, C3++ IIb 0/21 4
8 IgG+, IgA+++, IgM+, C3+ IIb 0/5 2
9 IgA++ IIb 0/25 4
10 IgG+-, IgA++, C3 + IIb 0/31 4
11 IgG+, IgA+++, C3++ IIb 0/18 4
Figure 1 - Histopathology of kidney biopsies. Figure 1A and 1B: A typical representation of DEP-HSPN characterized by significant
endothelial proliferation. Figure 1C and 1D: A typical representation of non-DEP-HSPN characterized by significant mesangial cell
proliferation. Biopsy samples were prepared by routine H&E staining (Figure 1A and 1C) or PAS staining (Figure 1B and 1D).
Magnification = x200.
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especially Tripterygium alone, were effective in reducing
proteinuria.
In clinical practice, renal biopsies are rarely used to eval-
uate therapeutic efficacy. Furthermore, reducing or dis-
continuing an effective therapy in a patient is often carried
out without confirming whether the nephritis has improved
pathologically. As a result, relapse often occurs in patients
who appear to have had a remission, but there is no
improvement in their renal histopathology. In this study,
repeat renal biopsies were not performed in the 11 cases of
DEP-HSPN to monitor renal histopathological improve-
ments and guide the therapeutic strategy, which was one of
the major limitations of the current study.
The current study describes 11 cases of DEP-HSPN
in comparison to cases of non-DEP-HSPN. DEP-HSPN
had a higher prevalence of nephrotic syndrome but a
lower prevalence of hematuria. Histopathologically, IgA,
IgG and IgM antibody deposition was found in DEP-
HSPN. After standard treatment with steroids and/or
immunosuppressive drugs, proteinuria cleared in all 11
cases. However, half of the DEP-HSPN patients continu-
ously had hematuria for as long as 20 months; thus,
hematuria in DEP-HSPN needs to be monitored for a
longer period.
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